This is clearly not a 'cowboy' company. This months events were well and truly flagged in the Quarterly released on 31 October i.e. the commencement of the pivotal trial in November. Additionally, much of last Friday's trade - and today's - would have been a response to the announcement re the NSW Medical Devices Fund grant.
The trading last week was not exceptional. Quite ordered I would have thought and a totally predictable response to the market's understanding of the imminent trial commencement!
EMV Price at posting:
$1.78 Sentiment: Buy Disclosure: Held
